The average analysts' target price is $36.80 for Aerie Pharmaceuticals using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Aerie Pharmaceuticals is ranked 95.
Aerie Pharmaceuticals rank is 487
Aerie Pharmaceuticals has a low Put/Call ratio of 0.28 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Aerie Pharmaceuticals is ranked 764.
|90 Day Gain
Aerie Pharmaceuticals rank is 2658
|Down EPS Surprise
Aerie Pharmaceuticals missed the consensus earnings estimate when it last reported quarterly earnings.
Within the past 90 days Aerie Pharmaceuticals has provided guidance belwo the consensus estimates. Statistics show companies that provide negative guidance underperform the market in the short-term.
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Aerie Pharmaceuticals is ranked 286.
|Down Ratings Revision
During the past month, the average analyst's rating or recommendation has decreased. Among companies that have been downgraded within the past month, Aerie Pharmaceuticals is ranked 295.
|10 Day Loss
Aerie Pharmaceuticals rank is 698
Aerie Pharmaceuticals has a high Put/Call ratio of 0.23 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Aerie Pharmaceuticals is ranked 1342.